Post by Sofinnova Partners

𝗠𝘆𝗿𝗶𝗰𝘅 𝗕𝗶𝗼 𝗮𝗴𝗿𝗲𝗲𝘀 𝘁𝗼 𝗯𝗲 𝗮𝗰𝗾𝘂𝗶𝗿𝗲𝗱 𝗯𝘆 𝗡𝗼𝘃𝗮𝗿𝘁𝗶𝘀 We're delighted to share that our portfolio company Myricx Bio has agreed to be acquired by Novartis in deal worth up to $1.5B, marking Sofinnova Partners's seventh exit in three years. We've proudly backed Myricx Bio since its founding in 2019.From the very beginning, we worked alongside the founding team to spin the company out of Imperial College London and The Francis Crick Institute, providing seed funding together with Brandon Capital. It’s been incredible to watch the company grow from an ambitious scientific vision into a leader in one of the most exciting areas of oncology. Myricx has built a truly differentiated ADC platform, with lead programs targeting B7-H3 and HER2 across multiple solid tumor indications. This is what's possible when world-class academic science is paired with committed, early-stage venture support, exactly what Sofinnova exists to do. Congratulations to the entire Myricx Bio team, CEO Mohit Rawat, and to our co-investors who backed this journey alongside us👏. Link to press release in the comments. Mohit Rawat, Robin Carr, 𝗥𝗼𝗯𝗲𝗿𝘁𝗼 𝗦𝗼𝗹𝗮𝗿𝗶, Ed Tate, Andy Bell, Chris Martin, Jonathan Tobin, Jayson Punwani, Michael Karl Bauer, Abingworth, Novo Holdings, Brandon Capital, Eli Lilly and Company 𝗩𝗲𝗻𝘁𝘂𝗿𝗲𝘀, British Business Bank, Imperial College London, The Francis Crick Institute